ArticleJMIR dermatology2025
Teledermatology to Support Self-Care in Chronic Spontaneous Urticaria.
Article in JMIR dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlabelled: Chronic spontaneous urticaria (CSU) is an autoimmune prompted skin disorder, whose hallmarks include the unpredictable onset of hives and itch. Symptom duration typically exceed 6 weeks, and flares can occur for up to 5 years or longer if untreated, impacting potentially any area of the body. The absence of obvious triggers and the variation in onset frequency often delays formal diagnosis which on average is approximately 2 years from first presentation. Initial standard of care is the use of low through to higher strength antihistamines in the first instance, with eventual escalation to prescription anti-inflammatory agents and potentially biologics once patients are under managed care. The societal impacts of delays in diagnosis are marked, with data suggesting CSU impacts up to 1% of the population, primarily of working age and with twice the prevalence in women. Herein, we advocate for the deployment of smartphone imaging and generative artificial intelligence technology to improve detection and early management of CSU through integrated self-care approaches. Such approaches embodying the tenets of P4 personalized medicine could have sustained impact on the disease through awareness campaigns, reducing the burden on the dermatology community and facilitating earlier access to curative therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.